Option chain shows key data for Dermata Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Dermata Therapeutics.

Dermata Therapeutics (NASDAQ:DRMA) Stock, Option Chain

Dermata Therapeutics

Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Macro,View,Of,Stacks,Of,Gold,Bars

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AUUD

DRMA

GTEC

SLNO

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Asian,Woman,Facial,Skin,With,Red,Spots,And,Swelling,After

Biotech

Health Care

Movers

General

Dermata&#39;s Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025.

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Nasdaq index

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

Contracts

Press Releases

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Offerings

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata to Present on BioPub on January 31, 2025

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

DRMAW

RVNC

Aditxt

AIM ImmunoTech

Ainos

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Mainz Biomed

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Portage Biotech

Plus Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

SILO Pharma

Soligenix

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Dermata Therapeutics

Dermata Therapeutics (DRMA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga